Ultrasound-guided fine-needle aspiration biopsies (FNA) accurately identify 62-85 per cent of thyroid nodules as benign. For those deemed malignant or unclassifiable, surgery is currently required. However, about 20-35 per cent of nodules have inconclusive results after FNA. This novel test classifies genes from the thyroid nodule tissue obtained through FNA.
"This test, currently available at Penn Medicine, can help us determine whether these nodules with indeterminate biopsy results are likely to be benign," said Doctor Susan Mandel."If so, patients may be able to avoid unnecessary surgeries and lifelong thyroid hormone replacement treatment."
"In this era of focusing on high-quality outcomes at lower cost, this new gene expression classifier test is a welcome addition to the tools available for informed decision making about the management of thyroid nodules," says Doctor J. Larry Jameson.
The gene expression classifier was tested on 265 indeterminate thyroid nodules, and was able to correctly identify 92 per cent of cases as suspicious. The test demonstrated a 85 - 95 per cent negative predictive value, effectively ruling out a malignancy.
MEDICA.de; Source: University of Pennsylvania